EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access · CC BY 4.0

Multidisciplinary Inferior Vena Cava Reconstruction for Malignancy: Outcomes of 53 Consecutive Patients and Retrospective Concordance with the 2025 Delphi Consensus

Caroline Caradu, Quentin Balézeaux, Quentin Toyen, Claire Webster, Magalie Fau, Eric Ducasse, Xavier Bérard

Current Oncology · 17.11.2026 · 33 (11) · 711

DOI: 10.3390/curroncol33110711 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift Current Oncology, online erschienen am 17.11.2026. Verfasst von Caroline Caradu und 6 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumours involving the inferior vena cava are rare and require complex oncovascular surgery, for which standardised recommendations have only recently been proposed. This study evaluated perioperative, oncological, and vascular outcomes of inferior vena cava resection and reconstruction in a contemporary multidisciplinary cohort and assessed its retrospective concordance with the 2025 Delphi Consensus. We retrospectively reviewed 53 consecutive patients undergoing surgery for malignant tumours involving the inferior vena cava at a tertiary referral centre between February 2009 and April 2022. Clinical, operative, postoperative, oncological, and vascular outcomes were collected from a prospectively maintained database. Vena cava reconstruction was performed in 48 patients (91%), predominantly using ringed polytetrafluoroethylene interposition grafts. Complete (R0) tumour resection was achieved in 72% of patients. R0 resection was associated with significantly better 5-year overall survival (59.0% vs. 24.0%, p = 0.006) and recurrence-free survival (57.2% vs. 15.6%, p = 0.008) compared with R1 resection. In-hospital and 90-day mortality were 3.7% and 7.5%, respectively, while 21% required urgent reintervention during the index hospitalisation. At a median follow-up of 45 months, overall survival was 78.2% at 1 year and 48.7% at 5 years. Primary venous patency was 86.0% at 1 and 2 years and 78.4% at 5 years. Surgical management showed high retrospective concordance with the Delphi Consensus recommendations, published after the study period. Inferior vena cava oncovascular resection and reconstruction can be performed with acceptable early mortality and durable venous patency in experienced multidisciplinary centres. These findings support specialised referral and provide real-world data for further standardisation of reconstruction, anticoagulation, and surveillance strategies.

Zitieren

APA

Caradu, C., Balézeaux, Q., Toyen, Q., Webster, C., Fau, M., Ducasse, E., & Bérard, X. (2026). Multidisciplinary Inferior Vena Cava Reconstruction for Malignancy: Outcomes of 53 Consecutive Patients and Retrospective Concordance with the 2025 Delphi Consensus. Current Oncology, 33(11), 711. https://doi.org/10.3390/curroncol33110711

Vancouver

Caradu C, Balézeaux Q, Toyen Q, Webster C, Fau M, Ducasse E, et al. Multidisciplinary Inferior Vena Cava Reconstruction for Malignancy: Outcomes of 53 Consecutive Patients and Retrospective Concordance with the 2025 Delphi Consensus. Current Oncology. 2026;33(11):711. doi:10.3390/curroncol33110711

BibTeX
@article{Caradu2026,
  author = {Caradu, Caroline and Balézeaux, Quentin and Toyen, Quentin and Webster, Claire and Fau, Magalie and Ducasse, Eric and Bérard, Xavier},
  title = {Multidisciplinary Inferior Vena Cava Reconstruction for Malignancy: Outcomes of 53 Consecutive Patients and Retrospective Concordance with the 2025 Delphi Consensus},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {11},
  pages = {711},
  doi = {10.3390/curroncol33110711}
}
Kostenlos starten →